Treat-to-target urate-lowering therapy and hospitalizations for gout: results from a nationwide cohort study in England.

Mark D Russell, Edward Roddy, Andrew I Rutherford, Benjamin Ellis, Sam Norton, Abdel Douiri, Martin C Gulliford, Andrew P Cope, James B Galloway
Author Information
  1. Mark D Russell: Centre for Rheumatic Diseases, King's College London, London, UK. ORCID
  2. Edward Roddy: School of Medicine, Keele University, Keele, UK.
  3. Andrew I Rutherford: Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK. ORCID
  4. Benjamin Ellis: Department of Rheumatology, Imperial College Healthcare NHS Foundation Trust, London, UK.
  5. Sam Norton: Centre for Rheumatic Diseases, King's College London, London, UK. ORCID
  6. Abdel Douiri: School of Population Health and Environmental Sciences, King's College London, London, UK.
  7. Martin C Gulliford: School of Population Health and Environmental Sciences, King's College London, London, UK. ORCID
  8. Andrew P Cope: Centre for Rheumatic Diseases, King's College London, London, UK.
  9. James B Galloway: Centre for Rheumatic Diseases, King's College London, London, UK.

Abstract

OBJECTIVE: To investigate associations between treat-to-target urate-lowering therapy (ULT) and hospitalizations for gout.
METHODS: Using linked Clinical Practice Research Datalink and NHS Digital Hospital Episode Statistics data, we described the incidence and timing of hospitalizations for flares in people with index gout diagnoses in England from 2004-2020. Using Cox proportional hazards and propensity models, we investigated associations between ULT initiation, serum urate target attainment, colchicine prophylaxis, and the risk of hospitalizations for gout.
RESULTS: Of 292 270 people with incident gout, 7719 (2.64%) had one or more hospitalizations for gout, with an incidence rate of 4.64 hospitalizations per 1000 person-years (95% CI 4.54, 4.73). There was an associated increased risk of hospitalizations within the first 6 months after ULT initiation, when compared with people who did not initiate ULT [adjusted Hazard Ratio (aHR) 4.54; 95% CI 3.70, 5.58; P < 0.001]. Hospitalizations did not differ significantly between people prescribed vs not prescribed colchicine prophylaxis in fully adjusted models. From 12 months after initiation, ULT associated with a reduced risk of hospitalizations (aHR 0.77; 95% CI 0.71, 0.83; P < 0.001). In ULT initiators, attainment of a serum urate <360 micromol/l within 12 months of initiation associated with a reduced risk of hospitalizations (aHR 0.57; 95% CI 0.49, 0.67; P < 0.001) when compared with people initiating ULT but not attaining this target.
CONCLUSION: ULT associates with an increased risk of hospitalizations within the first 6 months of initiation but reduces hospitalizations in the long term, particularly when serum urate targets are achieved.

Keywords

References

  1. JAMA. 2016 Jun 7;315(21):2345-7 [PMID: 27272587]
  2. J Clin Rheumatol. 2009 Sep;15(6):271-4 [PMID: 19734730]
  3. Arthritis Care Res (Hoboken). 2020 Jun;72(6):744-760 [PMID: 32391934]
  4. Rheumatology (Oxford). 2021 Dec 24;61(1):90-102 [PMID: 34247233]
  5. BMC Med. 2017 Aug 18;15(1):158 [PMID: 28818081]
  6. Ann Rheum Dis. 2017 Jan;76(1):29-42 [PMID: 27457514]
  7. J Rheumatol Suppl. 2014 Sep;92:42-7 [PMID: 25180127]
  8. Lancet Reg Health Eur. 2022 May 25;18:100416 [PMID: 35814340]
  9. Emerg Med J. 2017 Sep;34(9):627 [PMID: 28720722]
  10. Ann Rheum Dis. 2015 Apr;74(4):661-7 [PMID: 24431399]
  11. Arthritis Res Ther. 2022 Apr 20;24(1):88 [PMID: 35443675]
  12. Clin Rheumatol. 2018 Mar;37(3):825-830 [PMID: 29359231]
  13. J Rheumatol. 2020 Apr;47(4):619-623 [PMID: 31523046]
  14. Curr Ther Res Clin Exp. 2013 Dec;75:1-4 [PMID: 24465034]
  15. Semin Arthritis Rheum. 2015 Aug;45(1):75-80 [PMID: 25912932]
  16. Arthritis Care Res (Hoboken). 2017 May;69(5):758-762 [PMID: 27565008]
  17. JAMA. 2022 Aug 2;328(5):440-450 [PMID: 35916846]
  18. Br J Clin Pharmacol. 1997 Aug;44(2):175-8 [PMID: 9278205]
  19. J Public Health (Oxf). 2012 Mar;34(1):138-48 [PMID: 21795302]
  20. Lancet. 2018 Oct 20;392(10156):1403-1412 [PMID: 30343856]
  21. Br J Clin Pharmacol. 2010 Jan;69(1):4-14 [PMID: 20078607]
  22. J Rheumatol. 2022 Jul;49(7):725-730 [PMID: 35293331]
  23. Rheumatology (Oxford). 2017 Jul 1;56(7):1246 [PMID: 28605531]

Grants

  1. NIHR300967/National Institute for Health and Care Research

MeSH Term

Humans
Uric Acid
Cohort Studies
Gout Suppressants
Gout
Hospitalization
Colchicine
England

Chemicals

Uric Acid
Gout Suppressants
Colchicine

Word Cloud

Created with Highcharts 10.0.0hospitalizationsULTgout0peopleinitiationrisk495%CIurate-loweringtherapyserumurateassociatedwithinaHRP < 0associationstreat-to-targetUsingincidenceEnglandmodelstargetattainmentcolchicineprophylaxis54increasedfirst6 monthscomparedprescribed12 monthsreduced001OBJECTIVE:investigateMETHODS:linkedClinicalPracticeResearchDatalinkNHSDigitalHospitalEpisodeStatisticsdatadescribedtimingflaresindexdiagnoses2004-2020CoxproportionalhazardspropensityinvestigatedRESULTS:292 270incident7719264%onerate64per1000person-years73initiate[adjustedHazardRatio370558001]Hospitalizationsdiffersignificantlyvsfullyadjusted777183initiators<360micromol/l574967initiatingattainingCONCLUSION:associatesreduceslongtermparticularlytargetsachievedTreat-to-targetgout:resultsnationwidecohortstudycrystalarthritis

Similar Articles

Cited By